Tyler-Stone Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Tyler-Stone Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-127	Closed	-$6.86K	–	435
2024 Q2	$6.86K	Sell	127 -100	-44%	-$5.78K	﹤0.01%	706
2024 Q1	$15.5K	Hold	227	–	–	0.01%	575
2023 Q4	$14.2K	Hold	227	–	–	0.01%	569
2023 Q3	$10K	Hold	227	–	–	0.01%	608
2023 Q2	$13K	Buy	+227	New	+$12.9K	0.01%	549
2022 Q4	$9K	Hold	227	–	–	0.01%	567
2022 Q3	$15K	Hold	227	–	–	0.01%	472
2022 Q2	$14K	Buy	227 +27	+14%	+$1.59K	0.01%	501
2022 Q1	$13K	Hold	200	–	–	0.01%	524
2021 Q4	$15K	Buy	+200	New	+$17.5K	0.01%	523

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Tyler-Stone Wealth Management's CRSP Position: Q3 2024 in Review

Tyler-Stone Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 127 shares — an estimated $6.86K sold.

Tyler-Stone Wealth Management first reported a position in CRSP in Q4 2021 and held it in 10 quarters. The position peaked at $15.5K in Q1 2024. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

Tyler-Stone Wealth Management reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
Tyler-Stone Wealth Management sold 127 CRISPR Therapeutics shares in Q3 2024, an estimated $6.86K.
Tyler-Stone Wealth Management first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 10 quarters.
Tyler-Stone Wealth Management's CRISPR Therapeutics position peaked at $15.5K in Q1 2024.
416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Tyler-Stone Wealth Management's 13F filing for Q3 2024, filed 4 Nov 2024.